OXFORD - Britain's biotech sector has been given a welcome if modest boost with the news that Scotia Holdings (LSE:SOH) has signed licensing deals worth potentially in excess of $100 million.

SOH (Stirling, U.K.) signed licensing agreements with Boehringer Ingelheim and Kyowa Hakko Kogyo for the development and commercialization of Foscan, its photodynamic therapy (PDT) agent for cancer and pre-malignant conditions.